Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: Annual General Meeting of April 30, 2025
12:46pm, Wednesday, 30'th Apr 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board compo
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
07:00am, Wednesday, 30'th Apr 2025
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
Sanofi (SNY) Q1 2025 Earnings Call Transcript
02:03pm, Thursday, 24'th Apr 2025
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
09:00am, Thursday, 24'th Apr 2025
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
04:48am, Thursday, 24'th Apr 2025
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
Innate Pharma Announces €15M Investment by Sanofi
01:35am, Thursday, 24'th Apr 2025
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increa
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
01:33am, Thursday, 24'th Apr 2025
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
01:30am, Thursday, 24'th Apr 2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
02:44am, Wednesday, 23'rd Apr 2025
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
01:00am, Wednesday, 23'rd Apr 2025
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Resea
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
10:10am, Tuesday, 22'nd Apr 2025
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
10:25am, Monday, 21'st Apr 2025
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
11:31am, Friday, 18'th Apr 2025
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
11:15am, Friday, 18'th Apr 2025
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and
